ArticleAnalytical and bioanalytical chemistry2026
SEC-based isolation of phosphatidylserine-liposomes from biological samples for preclinical studies.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Autoimmune diseases represent a significant clinical challenge due to their high prevalence, chronic progression, and profound impact on patients' quality of life. Despite advances in understanding their pathophysiological mechanisms, in most cases, only palliative treatments are available. In this regard, a novel therapeutic approach is under development, using phosphatidylserine-liposomes (PS-Liposomes) encapsulating specific antigenic peptides that trigger the autoimmune attack. By varying the encapsulated antigen, this method offers the potential to treat different autoimmune diseases. The development of robust bioanalytical methods to characterize PS-Liposomes in biological fluids is of great importance to evaluate their efficacy and safety in preclinical trials. This presents a significant challenge due to the presence of extracellular vesicles and proteins in blood with similar size and composition to PS-Liposomes. In this study, size exclusion chromatography (SEC) was assessed for the isolation of PS-Liposomes encapsulating acetylcholine receptor peptide (AChR), intended for myasthenia gravis treatment, from minipig serum samples. A home-packed column filled with Sepharose 2B-CL resin and two commercial columns with agarose resin (qEV 35 nm and qEV 70 nm) were tested by using fluorescently labelled PS-Liposomes. Fractions containing PS-Liposomes were monitored by flow cytometry and qEV columns were selected for further experiments. For PS-liposome preconcentration of the obtained fractions, two different methodologies were also evaluated (Centrisart filters and qEV kit). Lipid and antigenic peptide recoveries obtained for each method were determined by HPLC-ELSD and HPLC-MS, and the optimum isolation and preconcentration approach was selected. Finally, the established methodology was successfully applied to spiked minipig serum with unlabelled PS-Liposomes, and the preservation of structural integrity after isolation was demonstrated by nanoparticle tracking analysis (NTA) and scanning electron microscopy (SEM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.